FDA Approves IMCIVREE for Hypothalamic Obesity Treatment
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy RYTM?
Source: NASDAQ.COM
- FDA Approval: Rhythm Pharmaceuticals announced that IMCIVREE has received FDA approval, becoming the first and only therapy cleared for the treatment of acquired hypothalamic obesity, marking a significant breakthrough in this rare and severe condition.
- Clinical Trial Results: In the global Phase 3 TRANSCEND trial involving 142 patients, IMCIVREE achieved a placebo-adjusted BMI reduction of -18.4%, with treated patients showing a -15.8% mean BMI decrease compared to a +2.6% increase in the placebo group, demonstrating significant efficacy.
- Market Potential: With approximately 10,000 people in the U.S. living with acquired hypothalamic obesity, IMCIVREE is now available to U.S. patients, expected to meet the urgent needs of this specific population and drive revenue growth for the company.
- Revenue Growth: IMCIVREE generated $57.3 million in global net product revenue in Q4 2025, a 12% increase from $51.1 million in Q3, and a significant rise from $41.8 million in Q4 2024, indicating improved market acceptance.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy RYTM?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on RYTM
Wall Street analysts forecast RYTM stock price to rise
15 Analyst Rating
14 Buy
1 Hold
0 Sell
Strong Buy
Current: 85.860
Low
123.00
Averages
140.62
High
167.00
Current: 85.860
Low
123.00
Averages
140.62
High
167.00
About RYTM
Rhythm Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its lead asset, IMCIVREE, as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. IMCIVREE is approved by the Food and Drug Administration (FDA) for chronic weight management in adult and pediatric patients six years of age and older with monogenic or syndromic obesity due to proopiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1) or leptin receptor (LEPR) deficiency as determined by an FDA-approved test demonstrating variants in POMC, PCSK1, or LEPR genes that are interpreted as pathogenic, likely pathogenic, or of uncertain significance (VUS). In addition to setmelanotide, it has two earlier-stage investigational MC4R agonists in clinical development, RM-718, designed for weekly administration, and bivamelagon, an oral small molecule.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
FDA Approves IMCIVREE for Hypothalamic Obesity Treatment
- FDA Approval: Rhythm Pharmaceuticals announced that IMCIVREE has received FDA approval, becoming the first and only therapy cleared for the treatment of acquired hypothalamic obesity, marking a significant breakthrough in this rare and severe condition.
- Clinical Trial Results: In the global Phase 3 TRANSCEND trial involving 142 patients, IMCIVREE achieved a placebo-adjusted BMI reduction of -18.4%, with treated patients showing a -15.8% mean BMI decrease compared to a +2.6% increase in the placebo group, demonstrating significant efficacy.
- Market Potential: With approximately 10,000 people in the U.S. living with acquired hypothalamic obesity, IMCIVREE is now available to U.S. patients, expected to meet the urgent needs of this specific population and drive revenue growth for the company.
- Revenue Growth: IMCIVREE generated $57.3 million in global net product revenue in Q4 2025, a 12% increase from $51.1 million in Q3, and a significant rise from $41.8 million in Q4 2024, indicating improved market acceptance.
See More
Rhythm Pharmaceuticals' Lead Candidate Fails Key Clinical Trial Goal
- Clinical Trial Outcome: Rhythm Pharmaceuticals' lead candidate setmelanotide failed to meet the primary endpoint in the EMANATE trial, resulting in a ~3% drop in premarket trading, indicating concerns over the drug's efficacy in treating certain rare obesity forms.
- Trial Design and Findings: The placebo-controlled trial included four independent genetic substudies aimed at evaluating setmelanotide's effects on rare genetic obesity linked to the MC4R pathway; while the primary endpoint was not met, significant BMI reductions were observed in specific subgroups, suggesting potential clinical relevance.
- Safety Assessment: According to Rhythm, the EMANATE trial did not indicate any new safety signals, confirming that setmelanotide remains safe for use in other rare obesity disorders, which may support future market applications.
- Future Outlook: Despite the EMANATE trial's failure to meet its primary endpoint, Rhythm remains encouraged by positive signals from the POMC/PCSK1 and SRC1 substudies, with the CEO affirming ongoing drug development and projecting non-GAAP operating expenses of $385M to $415M in 2026, reflecting confidence in future growth.
See More
Rhythm Pharmaceuticals Releases EMANATE Trial Results for Setmelanotide
- Trial Overview: Rhythm Pharmaceuticals' global Phase 3 EMANATE trial results for Setmelanotide indicate that while primary endpoints were not met, significant BMI reductions of -9.7% and -8.0% were observed in POMC/PCSK1 and SRC1 heterozygous patients at 52 weeks, respectively, providing critical data for future treatment strategies.
- Patient Group Analysis: Among the four genetic subgroups, POMC/PCSK1 patients (n=78) showed a 4.3% BMI reduction, LEPR patients (n=23) a 3.6% reduction, SRC1 patients (n=73) a 4.0% reduction, and SH2B1 patients (n=121) a 1.7% reduction, highlighting the differential treatment responses based on genetic variants.
- Safety Assessment: No new safety concerns emerged during the trial, with common side effects including skin reactions, nausea, vomiting, and headache, indicating a favorable safety profile for Setmelanotide and supporting its broader application in the patient population.
- Future Development Directions: Rhythm plans to continue analyzing EMANATE data to guide development paths for SRC1 and POMC subgroups while advancing next-generation MC4R agonists Bivamelagon and RM-718, demonstrating the company's ongoing commitment to addressing rare genetic obesity.
See More
Rhythm Pharmaceuticals Reports Positive Phase 3 Trial Data for Setmelanotide
- Significant BMI Reduction: Rhythm Pharmaceuticals reported an 18.8% placebo-adjusted difference in BMI reduction at 52 weeks in the TRANSCEND trial, indicating a positive outlook for treating acquired hypothalamic obesity, which may bolster investor confidence.
- Primary Endpoint Achieved: The trial involved 142 patients, with 94 receiving setmelanotide therapy showing a mean BMI reduction of 16.4%, while the placebo group experienced a 2.4% increase, highlighting the drug's efficacy.
- Hunger Score Improvement: Among patients aged 12 and older, the setmelanotide group showed an average weekly reduction of 2.5 points in hunger scores compared to a 1.3-point reduction in the placebo group, demonstrating the drug's potential in appetite control.
- FDA Application Progress: The company has submitted a supplemental New Drug Application for setmelanotide to the FDA, with a decision expected by March 20, which could position it as the first approved treatment for this condition, enhancing market appeal.
See More
Rhythm Pharmaceuticals Reports Positive Phase 3 Results for Obesity Treatment
- Clinical Trial Results: Rhythm Pharmaceuticals' global Phase 3 TRANSCEND trial demonstrated a mean BMI reduction of 16.4% in patients treated with Setmelanotide over 52 weeks, contrasting with a 2.4% increase in the placebo group, indicating significant efficacy.
- Patient Cohort Analysis: Among the 142 participants, including a Japanese cohort, the results highlighted Setmelanotide's superior performance in weight reduction and hunger score improvement, particularly in patients aged 12 and older.
- Regulatory Application Progress: Rhythm has submitted a supplemental New Drug Application (sNDA) to the U.S. FDA, with a PDUFA goal date of March 20, 2026, while also pursuing regulatory reviews in Europe and Japan, with potential approvals expected later this year.
- Market Performance: RYTM's stock has traded between $45.90 and $122.20 over the past year, closing at $92.73, down 5.45%, but showing a slight recovery of 0.08% in after-hours trading, reflecting market interest in the new therapy.
See More
Rhythm Pharmaceuticals Reports Positive Data on Weight Loss Therapy Setmelanotide
- Clinical Trial Results: Rhythm Pharmaceuticals' global Phase 3 TRANSCEND trial data for 142 patients at 52 weeks shows an 18.8% placebo-adjusted difference in BMI reduction, with a mean BMI decrease of 16.4% in 94 patients on setmelanotide compared to a 2.4% increase in the placebo group, indicating significant efficacy.
- Hunger Score Improvement: Among patients aged 12 and older, the setmelanotide group experienced an average weekly reduction of 2.5 points in hunger scores, compared to a 1.3-point reduction in the placebo group, with statistical significance at p=0.0015, highlighting the drug's potential in hunger management.
- Regulatory Progress: Rhythm's supplemental New Drug Application (sNDA) is under review by the FDA with a PDUFA goal date of March 20, 2026, and the final data package is expected to be submitted on March 2, 2026, further advancing market access.
- International Market Expansion: The company plans to submit a marketing authorization application for setmelanotide to Japan's PMDA and anticipates receiving marketing authorization from the European Commission in the second half of 2026, demonstrating its strategic global positioning and market potential.
See More
FDA Approves IMCIVREE for Hypothalamic Obesity Treatment
- FDA Approval: Rhythm Pharmaceuticals announced that IMCIVREE has received FDA approval, becoming the first and only therapy cleared for the treatment of acquired hypothalamic obesity, marking a significant breakthrough in this rare and severe condition.
- Clinical Trial Results: In the global Phase 3 TRANSCEND trial involving 142 patients, IMCIVREE achieved a placebo-adjusted BMI reduction of -18.4%, with treated patients showing a -15.8% mean BMI decrease compared to a +2.6% increase in the placebo group, demonstrating significant efficacy.
- Market Potential: With approximately 10,000 people in the U.S. living with acquired hypothalamic obesity, IMCIVREE is now available to U.S. patients, expected to meet the urgent needs of this specific population and drive revenue growth for the company.
- Revenue Growth: IMCIVREE generated $57.3 million in global net product revenue in Q4 2025, a 12% increase from $51.1 million in Q3, and a significant rise from $41.8 million in Q4 2024, indicating improved market acceptance.
See More
Rhythm Pharmaceuticals' Lead Candidate Fails Key Clinical Trial Goal
- Clinical Trial Outcome: Rhythm Pharmaceuticals' lead candidate setmelanotide failed to meet the primary endpoint in the EMANATE trial, resulting in a ~3% drop in premarket trading, indicating concerns over the drug's efficacy in treating certain rare obesity forms.
- Trial Design and Findings: The placebo-controlled trial included four independent genetic substudies aimed at evaluating setmelanotide's effects on rare genetic obesity linked to the MC4R pathway; while the primary endpoint was not met, significant BMI reductions were observed in specific subgroups, suggesting potential clinical relevance.
- Safety Assessment: According to Rhythm, the EMANATE trial did not indicate any new safety signals, confirming that setmelanotide remains safe for use in other rare obesity disorders, which may support future market applications.
- Future Outlook: Despite the EMANATE trial's failure to meet its primary endpoint, Rhythm remains encouraged by positive signals from the POMC/PCSK1 and SRC1 substudies, with the CEO affirming ongoing drug development and projecting non-GAAP operating expenses of $385M to $415M in 2026, reflecting confidence in future growth.
See More
Rhythm Pharmaceuticals Releases EMANATE Trial Results for Setmelanotide
- Trial Overview: Rhythm Pharmaceuticals' global Phase 3 EMANATE trial results for Setmelanotide indicate that while primary endpoints were not met, significant BMI reductions of -9.7% and -8.0% were observed in POMC/PCSK1 and SRC1 heterozygous patients at 52 weeks, respectively, providing critical data for future treatment strategies.
- Patient Group Analysis: Among the four genetic subgroups, POMC/PCSK1 patients (n=78) showed a 4.3% BMI reduction, LEPR patients (n=23) a 3.6% reduction, SRC1 patients (n=73) a 4.0% reduction, and SH2B1 patients (n=121) a 1.7% reduction, highlighting the differential treatment responses based on genetic variants.
- Safety Assessment: No new safety concerns emerged during the trial, with common side effects including skin reactions, nausea, vomiting, and headache, indicating a favorable safety profile for Setmelanotide and supporting its broader application in the patient population.
- Future Development Directions: Rhythm plans to continue analyzing EMANATE data to guide development paths for SRC1 and POMC subgroups while advancing next-generation MC4R agonists Bivamelagon and RM-718, demonstrating the company's ongoing commitment to addressing rare genetic obesity.
See More
Rhythm Pharmaceuticals Reports Positive Phase 3 Trial Data for Setmelanotide
- Significant BMI Reduction: Rhythm Pharmaceuticals reported an 18.8% placebo-adjusted difference in BMI reduction at 52 weeks in the TRANSCEND trial, indicating a positive outlook for treating acquired hypothalamic obesity, which may bolster investor confidence.
- Primary Endpoint Achieved: The trial involved 142 patients, with 94 receiving setmelanotide therapy showing a mean BMI reduction of 16.4%, while the placebo group experienced a 2.4% increase, highlighting the drug's efficacy.
- Hunger Score Improvement: Among patients aged 12 and older, the setmelanotide group showed an average weekly reduction of 2.5 points in hunger scores compared to a 1.3-point reduction in the placebo group, demonstrating the drug's potential in appetite control.
- FDA Application Progress: The company has submitted a supplemental New Drug Application for setmelanotide to the FDA, with a decision expected by March 20, which could position it as the first approved treatment for this condition, enhancing market appeal.
See More
Rhythm Pharmaceuticals Reports Positive Phase 3 Results for Obesity Treatment
- Clinical Trial Results: Rhythm Pharmaceuticals' global Phase 3 TRANSCEND trial demonstrated a mean BMI reduction of 16.4% in patients treated with Setmelanotide over 52 weeks, contrasting with a 2.4% increase in the placebo group, indicating significant efficacy.
- Patient Cohort Analysis: Among the 142 participants, including a Japanese cohort, the results highlighted Setmelanotide's superior performance in weight reduction and hunger score improvement, particularly in patients aged 12 and older.
- Regulatory Application Progress: Rhythm has submitted a supplemental New Drug Application (sNDA) to the U.S. FDA, with a PDUFA goal date of March 20, 2026, while also pursuing regulatory reviews in Europe and Japan, with potential approvals expected later this year.
- Market Performance: RYTM's stock has traded between $45.90 and $122.20 over the past year, closing at $92.73, down 5.45%, but showing a slight recovery of 0.08% in after-hours trading, reflecting market interest in the new therapy.
See More
Rhythm Pharmaceuticals Reports Positive Data on Weight Loss Therapy Setmelanotide
- Clinical Trial Results: Rhythm Pharmaceuticals' global Phase 3 TRANSCEND trial data for 142 patients at 52 weeks shows an 18.8% placebo-adjusted difference in BMI reduction, with a mean BMI decrease of 16.4% in 94 patients on setmelanotide compared to a 2.4% increase in the placebo group, indicating significant efficacy.
- Hunger Score Improvement: Among patients aged 12 and older, the setmelanotide group experienced an average weekly reduction of 2.5 points in hunger scores, compared to a 1.3-point reduction in the placebo group, with statistical significance at p=0.0015, highlighting the drug's potential in hunger management.
- Regulatory Progress: Rhythm's supplemental New Drug Application (sNDA) is under review by the FDA with a PDUFA goal date of March 20, 2026, and the final data package is expected to be submitted on March 2, 2026, further advancing market access.
- International Market Expansion: The company plans to submit a marketing authorization application for setmelanotide to Japan's PMDA and anticipates receiving marketing authorization from the European Commission in the second half of 2026, demonstrating its strategic global positioning and market potential.
See More
